Additionally, the off-target of many bipolar disorder treatments, the serotonin receptor 6 (HTR6), as well as calcium channel targets (e.g., CACNA1C, CACNA1B), which align with prior gene-set enrichment findings7, were linked to psychopharmaceuticals via GWAS signals. The gene discussed is CACNA1C; the disease is bipolar disorder.